Catalent Expert To Present At Peptalk 2012

Catalent Expert to Present On More Efficient Protein Expression in Cho Cells at Peptalk 2012

Somerset, NJ, January 4, 2012 — Gregory T. Bleck, Ph.D., Research and Development Platform Lead - Biologics for Catalent Pharma Solutions, will present “ Protein Expression in CHO Cells: Comparison of GPEx® to a Traditional Cell Line Engineering Technology ” at PepTalk 2012 – The Protein Science Week, being held in San Diego, CA on January 12, 2012. PepTalk 2012 is a weeklong program centered around protein-based therapeutics with a focus on formulation, purification, biotherapeutics and expression range. Dr. Bleck’s presentation, which will take place during the segment “Choosing, Designing, and Optimizing Hosts and Platforms,” will cover such areas as:

  • Evaluating cell line production and how it impacts the ability to produce hard to express proteins;
  • Identifying the advantages of GPEx® cell lines over traditional methods in protein production and stability; and
  • Analysis of the data resulting from a comparison between traditional and GPEx® cell line engineering technology.

GPEx® proprietary technology creates stable, high-yielding mammalian cell lines with high speed and efficiency getting drug development products to the clinic faster than traditional approaches.  The advantages of applying GPEx® technology include the rapid development for master cell banks within five months, and to date, over 250 different mAb and mAb fusions and over 60 different recombinant proteins have been produced using the GPEx® system.

Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics.  He has a broad background in Molecular Biology and Transgenic animals with 12 year’s experience within the organization.  Dr. Bleck holds a Bachelor’s degree in Dairy Science and a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Dr. Bleck has published more than 55 research papers and co-authored chapters in three books.

For more information on this event, please visit: .

To schedule an interview with the above mentioned presenter, during Peptalk 2012 or after, please contact Patricia McGee at .

To receive a copy of this presentation after the event, please visit us at .

Click here for more information on Catalent’s GPEx® technology .

About Catalent

Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries.  The company applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes.  Catalent employs more than 8,000 at 20+ facilities worldwide and in fiscal 2011 generated more than $1.6 billion in annual revenue.

more products. better treatments. reliably supplied.™